Clinical trial · Interventional
Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study proposes to conduct an open label, feasibility study administering prophylactic oral haldol to patients undergoing a hematopoietic stem cell transplant (HSCT). The study will address the following research aims: 1) To demonstrate the feasibility of enrolling HSCT patients in a prophylactic medication trial, 2) To determine the tolerability of oral haldol in HSCT patients and 2) To compare rates of delirium in HSCT patients who receive prophylactic haldol with an untreated historical control group.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Delirium | — | UNRESOLVED | — |
| Stem Cell Transplant Complications | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Haldol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Oral Haldol in patients undergoing HSCT
- description
- Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
- interventionNames
- Drug: Haldol
Primary outcomes (1)
- measure
- Side Effects and Tolerability of Haldol in Patients With Undergoing Hematopoietic Stem Cell Transplant
- timeFrame
- Daily, up to 14 days following transplant
- description
- Categorize and quantify adverse events from start of drug (day 1) to end of study drug per (CTCAE) version 4.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * The participant must undergo an autologous or allogeneic bone marrow or stem cell transplant * The participant is 18 years of age or older * The participant provides written consent Exclusion Criteria: * The participant has a QTc of \>450 msec at the time of enrollment * The participant used any antipsychotic medications within the last 30 days * The participant has any significant allergies or past intolerance to Haloperidol * The participant has a history of major neurological, metabolic, psychiatric, or cardiovascular disease, cerebrovascular event, or substance abuse * The participant has a history of mental retardation or learning disability that, at the discretion of the investigator, could affect their ability to complete study assessments.
References
Publications (0)
Data not yet available